A
Alessandro Testori
Researcher at European Institute of Oncology
Publications - 238
Citations - 25951
Alessandro Testori is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Melanoma & Sentinel node. The author has an hindex of 56, co-authored 228 publications receiving 23224 citations.
Papers
More filters
Journal ArticleDOI
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
TL;DR: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Journal ArticleDOI
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert,Luc Thomas,Igor Bondarenko,Steven J. O'Day,Jeffrey S. Weber,Claus Garbe,Céleste Lebbé,Jean Francois Baurain,Alessandro Testori,Jean-Jacques Grob,Neville Davidson,Jon M. Richards,Michele Maio,Axel Hauschild,Wilson H. Miller,Pere Gascón,Michal Lotem,Kaan Harmankaya,Ramy Ibrahim,Stephen Francis,Tai-Tsang Chen,R. Humphrey,Axel Hoos,Jedd D. Wolchok +23 more
TL;DR: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.
Journal ArticleDOI
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Alexander M.M. Eggermont,Vanna Chiarion-Sileni,Jean-Jacques Grob,Reinhard Dummer,Jedd D. Wolchok,Henrik Schmidt,Omid Hamid,Caroline Robert,Paolo A. Ascierto,Jon M. Richards,Céleste Lebbé,Virginia Ferraresi,Michael Smylie,Jeffrey S. Weber,Michele Maio,Lars Bastholt,Laurent Mortier,Luc Thomas,Saad Tahir,Axel Hauschild,Jessica C. Hassel,F. Stephen Hodi,Corina Taitt,Veerle de Pril,Gaetan de Schaetzen,Stefan Suciu,Alessandro Testori +26 more
TL;DR: As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence- free survival, overall survival, and distant metastasis-free survival than placebo.
Journal ArticleDOI
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M.M. Eggermont,Vanna Chiarion-Sileni,Jean-Jacques Grob,Reinhard Dummer,Jedd D. Wolchok,Henrik Schmidt,Omid Hamid,Caroline Robert,Paolo A. Ascierto,Jon M. Richards,C. Lebbé,Virginia Ferraresi,Michael Smylie,Jeffrey S. Weber,Michele Maio,Cyril Konto,Axel Hoos,Veerle de Pril,Ravichandra Karra Gurunath,Gaetan de Schaetzen,Stefan Suciu,Alessandro Testori +21 more
TL;DR: Adjuvant ipilimumab significantly improved recurrence-free survival for patients with completely resected high-risk stage III melanoma and the adverse event profile was consistent with that observed in advanced melanoma, but at higher incidences in particular for endocrinopathies.
Journal ArticleDOI
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Mark B. Faries,John F. Thompson,Alistair J. Cochran,Robert H.I. Andtbacka,Nicola Mozzillo,Jonathan S. Zager,Tiina Jahkola,Tawnya L. Bowles,Alessandro Testori,Peter D. Beitsch,Harald J. Hoekstra,Marc Moncrieff,Christian Ingvar,Michel W.J.M. Wouters,Michael S. Sabel,Edward A. Levine,Doreen M. Agnese,Michael A. Henderson,Reinhard Dummer,Carlo Riccardo Rossi,Rogerio I. Neves,Steven D. Trocha,Frances C. Wright,David R. Byrd,Maurice Matter,Eddy Hsueh,Alastair MacKenzie-Ross,Douglas B. Johnson,Patrick Terheyden,Adam C. Berger,Tara L. Huston,Jeffrey D. Wayne,B. Mark Smithers,Heather B. Neuman,Schlomo Schneebaum,Jeffrey E. Gershenwald,Charlotte E. Ariyan,Darius C. Desai,Lisa K. Jacobs,Kelly M. McMasters,Anja Gesierich,Peter Hersey,Steven D. Bines,John M. Kane,Richard J. Barth,Gregory McKinnon,Jeffrey M. Farma,Erwin S. Schultz,Sergi Vidal-Sicart,Richard A. Hoefer,James M. Lewis,Randall P. Scheri,Mark C. Kelley,Omgo E. Nieweg,R. Dirk Noyes,Dave S.B. Hoon,He-Jing Wang,David Elashoff,Robert Elashoff +58 more
TL;DR: Immediate completion lymph‐node dissection increased the rate of regional disease control and provided prognostic information but did not increase melanoma‐specific survival among patients with melanoma and sentinel‐node metastases.